This Company Wants to Rewrite the Future of Genetic Disease

Tessera Therapeutics is developing a new class of gene editors capable of precisely plugging in long stretches of DNA—something that Crispr can’t do.

from Feed: All Latest https://ift.tt/38B7ti7